Form 4: Clearside Biomedical Director Acquires Stock Options

William D. Humphries, a director of Clearside Biomedical, Inc., acquired stock options for 45,000 shares on June 20, 2024.

Summary

• On June 20, 2024, William D. Humphries, a director of Clearside Biomedical, Inc., acquired stock options.
• The stock options are for 45,000 shares of Clearside Biomedical's common stock.
• The exercise price of the stock options is $1.15.
• The options vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to continuous service.
• The options expire on June 19, 2034.

Sentiment

Score: 5

Explanation: This is a neutral event, simply a disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates